Michael Aitchison
Royal Free London NHS Foundation Trust
56 Papers
495 Citations
Michael Aitchison is an academic researcher from Royal Free London NHS Foundation Trust. The author has contributed to research in topics: Cancer & Nephrectomy. The author has an hindex of 23, co-authored 55 publications. Previous affiliations of Michael Aitchison include Beatson West of Scotland Cancer Centre & Royal Free Hospital.
Chat about Author
Papers
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
Arnaud Mejean,Alain Ravaud,Simon Thezenas,Sandra Colas,Jean-Baptiste Beauval,Karim Bensalah,Lionnel Geoffrois,Antoine Thiery-Vuillemin,Luc Cormier,Herve Lang,Laurent Guy,G. Gravis,Frederic Rolland,Claude Linassier,Eric Lechevallier,Christian Beisland,Michael Aitchison,Stéphane Oudard,Jean-Jacques Patard,Christine Theodore,Christine Chevreau,B. Laguerre,Jacques Hubert,Marine Gross-Goupil,Jean-Christophe Bernhard,Laurence Albiges,Marc-Olivier Timsit,Thierry Lebret,Bernard Escudier +28 more
TL;DR: Sunitinib alone was not inferior to nephrectomy followed by sunit inib in patients with metastatic renal‐cell carcinoma who were classified as having intermediate‐risk or poor‐risk disease.
848
Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer.
TL;DR: To examine the prognostic value of markers of systemic inflammatory response, together with established scoring systems, in predicting relapse‐free and cancer‐specific survival in patients with primary operable renal cancer, as there is increasing evidence that such markers provide prognostic information.
84
The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer.
TL;DR: The presence of a preoperative systemic inflammatory response predicts poor cancer-specific survival in patients who have undergone potentially curative resection for renal clear cell cancer.
Safety and efficacy of pazopanib therapy prior to planned nephrectomy in metastatic clear cell renal cancer
Thomas Powles,Naveed Sarwar,Andrew Stockdale,Shah-Jalal Sarker,Ekaterini Boleti,Andrew Protheroe,Robert Jones,Simon Chowdhury,John Peters,Grenville Oades,Tim O'Brien,Mark Sullivan,Michael Aitchison,Luis Beltran,Daniel C Worth,Katherine Smith,Constance Michel,Giorgia Trevisan,Elizabeth Harvey-Jones,Akhila Wimalasingham,Anju Sahdev,Charlotte Ackerman,Simon J. Crabb +22 more
TL;DR: Nephrectomy after upfront pazopanib therapy could be performed safely and was associated with good outcomes in patients with intermediate-risk metastatic clear cell renal cancer.